Navigation Links
Actavis Launches Generic Version of Flomax(R) In The U.S.
Date:4/27/2010

MORRISTOWN, N.J., April 27 /PRNewswire/ -- Actavis Inc., today began shipping Tamsulosin capsules to its customers in the United States. The generic equivalent to Flomax®, Tamsulosin is used to treat benign prostatic hyperplasia (BPH). Actavis is partnering with Synthon Pharmaceuticals to launch and market Tamsulosin capsules in the United States.  

Actavis offers Tamsulosin in a 0.4 mg strength capsule. Annual sales of Flomax® capsules in the U.S. were approximately US$2.17 billion for the 12 months ending December 2009, according to IMS Health data.  

About Actavis Inc.

Actavis Inc. is the U.S. subsidiary of Actavis Group hf. Approximately one quarter of Actavis' sales are generated in North America, Actavis' single largest market. Based in Morristown, NJ, Actavis has U.S. manufacturing facilities in Elizabeth, NJ; Little Falls, NJ; Totowa, NJ; and Lincolnton, NC. Actavis also has research and development facilities in Owings Mills, MD and Sunrise, FL; and a packaging facility in Totowa, NJ.

About Actavis Group

Actavis is one of the world's leading generic pharmaceutical companies specializing in the development, manufacture and sale of generic pharmaceuticals.  The company has operations in 40 countries, with more than 10,500 employees.

Information in this press release may contain forward-looking statements with respect to the financial condition, results of operations and businesses of Actavis.  By their nature, forward-looking statements and forecasts involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from that expressed or implied by these forward-looking statements. These factors include, among other things, exchange rate fluctuations, the risk that research and development will not yield new products that achieve commercial success, the impact of competition, price controls and price reductions, the risk of loss or expiration of patents or trade marks, difficulties of obtaining and maintaining governmental approvals for products, the risk of substantial product liability claims, exposure to environmental liability.


'/>"/>
SOURCE Actavis Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Actavis Receives Approval of Alprazolam ODT in the U.S.
2. The Vanishing Oath, the First Physician-Focused Documentary on the Dangers of the American Healthcare System, Launches on DVD May 5
3. NeoStem, Inc. Officially Launches Adult Stem Cell Collection Center and R&D Laboratory in Cambridge, Massachusetts
4. FDA Launches Initiative to Reduce Infusion Pump Risks
5. Usability Sciences Corporation Launches WebIQ Pharma - An Intelligent Survey Tool That Allows Pharma Sites to Measure and Improve Website Effectiveness
6. EndoChoice(R) Launches CEU Program on Proper Endoscope Reprocessing and a Line of Flexible Endoscope Reprocessing Products
7. VisEn Launches New VivoTag(R) 680 XL Fluorescence Molecular Imaging Label
8. CareFusion Launches New Pyxis ProcedureStation(TM) Radio Frequency Identification System at Association of Perioperative Registered Nurses 57th Annual Congress
9. ERT Launches Centralized Cardiac Safety 2.0: A Revolutionary New Approach to ECG Management in Clinical Trials
10. Smith & Nephew Orthopaedics Launches Versatile VLP(TM) FOOT Plating System
11. Blizzard, McCarthy & Nabers Launches ReglanJustice.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2017)... 2017 Zymo Research Corp., also known as ,The Epigenetics Company, ... aging in a precise manner using the myDNAge ™ test. Based ... professor of human genetics and biostatistics at the David Geffen School ... , Zymo Research,s proprietary DNAge ™ technology is used to analyze ... ...
(Date:7/11/2017)... JERUSALEM , July 11, 2017 Oramed ... ), a clinical-stage pharmaceutical company focused on the development ... U.S. Food and Drug Administration (FDA) has agreed to ... successfully completed Phase IIb trial of its oral insulin ... The Phase IIb trial met primary and secondary endpoints ...
(Date:7/10/2017)... , July 10, 2017 Locus Biosciences ... Note to support the development of CRISPR-Cas3 antimicrobial therapeutics. ... Limited, a leading Chinese Internet services provider, and joined ... advance multiple infectious disease product programs targeting antibiotic resistant ... Founded by Dr. Rodolphe Barrangou ...
Breaking Medicine Technology:
(Date:7/27/2017)... ... July 27, 2017 , ... Standard Process is ushering in a new era ... North Carolina Research Campus (NCRC) in Kannapolis, North Carolina and by announcing a new ... fall of this year, occupying over 10,000 square feet on the first floor of ...
(Date:7/27/2017)... ... 2017 , ... For bicycling enthusiasts around the globe, Germany's famous Rad am ... against a backdrop of tree-lined hills at the Nürburgring, a Formula One arena known ... Ring consists of some 73 curves, stretching out over more than 500 meters of ...
(Date:7/27/2017)... (PRWEB) , ... July 28, 2017 , ... ... Syngenta on an upcoming episode of the award-winning television series, American Famer, scheduled ... on RFD-TV. , Syngenta is dedicated to helping humanity face its toughest ...
(Date:7/27/2017)... OH (PRWEB) , ... July 27, 2017 , ... ... Electronic Visit Verification to State Medicaid programs, Managed Care Organizations and Home Care ... 2017. , The MEDsys platform, VinCENT, provides technology solutions to over 1,000 agencies ...
(Date:7/27/2017)... ... 2017 , ... GAFFEY Healthcare, a leading provider of revenue ... Vice President of Revenue Cycle Business Services and Suzanne Dusak to Vice President ... officer (CEO). , Elrene has been with company since Oct 2014 and previously ...
Breaking Medicine News(10 mins):